



ANDA 213409

ANDA APPROVAL

Ascend Laboratories, LLC
U.S. Agent for Alkem Laboratories Limited
339 Jefferson Road
Parsippany, NJ 07054
Attention: Hindy Schiff
Vice President, Regulatory Affairs

Dear Hindy Schiff:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on March 27, 2019, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Nimodipine Oral Solution, 30 mg/5 mL and 60 mg/10 mL (6 mg/mL) Unit-Dose Prefilled Oral Syringes and 60 mg/10 mL (6 mg/mL) Bottle.

Your product is a combination product as defined by 21 CFR 3.2(e) and is comprised of drug and device constituent parts.

Reference is also made to the tentative approval letter issued by this office on February 21, 2023, the complete response letter issued by this office on August 8, 2024, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Nimodipine Oral Solution, 30 mg/5 mL and 60 mg/10 mL (6 mg/mL) Unit-Dose Prefilled Oral Syringes and 60 mg/10 mL (6 mg/mL) Bottle, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nymalize Oral Solution, 6 mg/mL, of Azurity Pharmaceuticals, Inc. (Azurity) NDA - 203340.

The RLD upon which you have based your ANDA, Azurity's Nymalize Oral Solution, 6 mg/mL, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
10,342,787 (the '787 patent)	April 16, 2038
10,576,070 (the '070 patent)	April 16, 2038
11,207,306 (the '306 patent)	April 16, 2038
11,413,277 (the '277 patent)	April 16, 2038
11,806,338 (the '338 patent)	April 16, 2038

Your ANDA contains paragraph IV certifications to each of the patents, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Nimodipine Oral Solution, 30 mg/5 mL and 60 mg/10 mL (6 mg/mL) Unit-Dose Prefilled Oral Syringes and 60 mg/10 mL (6 mg/mL) Bottle, under this ANDA. You have notified the Agency that Alkem Laboratories Limited (Alkem) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. Litigation was initiated against Alkem for infringement of the '787, '070, '306 and '277 patents in the United States District Court for the District of New Jersey [Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., Civil Action No. 22-00143]. You have also notified the Agency that this case was dismissed.

With respect to 180-day generic drug exclusivity, we note that Alkem was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Nimodipine Oral Solution, 30 mg/5 mL and 60 mg/10 mL (6 mg/mL) Unit-Dose Prefilled Oral Syringes and 60 mg/10 mL (6 mg/mL) Bottle. Therefore, with this approval, Alkem is eligible for 180 days of generic drug exclusivity for Nimodipine Oral Solution, 30 mg/5 mL and 60 mg/10 mL (6 mg/mL) Unit-Dose Prefilled Oral Syringes and 60 mg/10 mL (6 mg/mL) Bottle. FDA notes that after issuance of this approval letter, eligibility for 180-day exclusivity is subject to future events that may result in forfeiture of exclusivity under section 505(j)(5)(D) of the FD&C Act. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, begins to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website at: <https://www.uspnf.com/>.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to: <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Catherine
Poole

Digitally signed by Catherine Poole

Date: 1/22/2025 07:30:50AM

GUID: 5407887a000a1c0c26055eafb8e3258a